Recombinant Human Insulin-like growth factor-binding protein 3 protein(IGFBP3) (Active)

In Stock
Code CSB-AP002491HU
Size US$3274Purchase it in Cusabio online store
(only available for customers from the US)
Image
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >98% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/ml, corresponding to a specific activity of >5.0x103 IU/mg in the presence of 15 ng/ml of rHuIGF-II.
Target Names IGFBP3
Uniprot No. P17936
Research Area Cancer
Alternative Names Acid stable subunit of the 140 K IGF complex; Binding protein 29; Binding protein 53; BP 53; BP53; Growth hormone dependent binding protein; IBP 3; IBP-3; IBP3; IBP3_HUMAN; IGF binding protein 3; IGF-binding protein 3; IGFBP 3; IGFBP-3; IGFBP3; Insulin Like Growth Factor Binding Protein 3; Insulin-like growth factor binding protein 3 precursor; Insulin-like growth factor-binding protein 3
Species Homo sapiens (Human)
Source E.coli
Expression Region 28-291aa(A32G,S148E)
Complete Sequence GASSGGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK
Mol. Weight 28.8 kDa
Protein Length Full Length of Mature Protein
Tag Info Tag-Free
Form Lyophilized powder
Buffer Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 5-10 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.
Gene References into Functions
  1. In cancerous tissues of colorectal cancer (CRC) patients, the miR197 level was inversely correlated with the expression of IGFBP3, which indicated that miR197 may modulate cell migration and invasion by targeting IGFBP3 in CRC patients. PMID: 30106114
  2. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression. PMID: 28393842
  3. B-Myb is an independent prognostic marker and serves as a potential target in the diagnosis and/or treatment of NSCLC, and that B-Myb functions as a tumor-promoting gene by targeting IGFBP3 in NSCLC cells. PMID: 29772705
  4. IGFBP-3 up-regulates PI3K/Akt/mTOR signaling pathway and down-regulates autophagy during cell aging. The decrease of IGFBP-3 expression in senescence and cell aging by H2O2 leads to up-regulation of mTOR and p53 signaling pathway, suggesting that IGFBP-3 could play a key role as an aging marker PMID: 29579543
  5. Low IGFBP-3 serum levels were associated with Pancreatic Cancer. PMID: 28681154
  6. IGFBP-3 Interacts with the Vitamin D Receptor in Insulin Signaling Associated with Obesity in Visceral Adipose Tissue PMID: 29112142
  7. IGFBP3, a gene associated with preeclampsia pathophysiology, was validated as a target gene of miR-210 PMID: 28653360
  8. analysis of IGFBP3-IGF1 correlation with the risk of esophageal carcinoma; the free form of IGFBP3, might be inversely associated with esophageal cancer incidence PMID: 28596684
  9. Our data indicate that targeting IGFBP-3-dependent signaling pathways through gefitinib-FTY720 co-therapy may be effective in many basal-like breast cancers, and suggest tissue IGFBP-3 and CD44 measurement as potential biomarkers of treatment efficacy. PMID: 28778177
  10. Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional ERalpha and endocrine responsiveness. Assessing ERalpha function (e.g., IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen PMID: 28073843
  11. In longitudinal analysis, changes of FGF-21 were not significantly related to changes of height, IGF-1 or IGFBP-3 in obese children. PMID: 26887040
  12. the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH PMID: 28300542
  13. We confirmed a previously reported association between circulating IGFBP-3 and diabetes risk in the older adult population PMID: 29040592
  14. The results of this study, while not clearly supporting associations between these obesity-related biomarkers and renal cell carcinoma risk, are consistent with previously reported findings for adiponectin, and suggest an association with elevated IGFBP-3 among obese individuals PMID: 28484923
  15. our results reveal a new function of IGFBP2, providing a novel insight into the mechanism of adipogenic differentiation and identifying a potential target mediator for improving adipose tissue engineering based on Wharton's jelly of the umbilical cord (WJCMSCs). PMID: 28859160
  16. Increased IGFBP3 level as associated with decreased risk of frailty in men. PMID: 28609827
  17. Functional IGFBP-3 was significantly lower in postmenopausal women than in premenopausal women, for both patients with rheumatoid arthritis and controls. There was a significant decrease in plasma functional IGFBP-3 levels in postmenopausal RA in comparison to healthy premenopausal subjects. PMID: 27775453
  18. study suggests high-order interactions of the IGFBP-3 rs2854744 AA genotype, BMI>/=24kg/m2, and DISI<9.85 mg/day on increased BC risk, particularly among postmenopausal women PMID: 27631779
  19. The stratification of individuals by gender revealed that Slovak males carrying IGFBP-3 G alleles (G32G or GG) had marginally increased risk for developing MDD as compared to CC homozygous males (p=0.09). In women, inverse association was observed between SNP rs1042522 and MDD risk (p=0.04 for recessive model). PMID: 27755861
  20. results indicate that hypoxia suppresses the osteogenic differentiation of mesenchymal stem cells via IGFBP3 up-regulation. PMID: 27563882
  21. Meta-analysis suggests that for esophageal cancer, the low IGFBP-3 level is associated with high cancer risk, poor prognosis, and unfavorable tumor stage and metastasis. [meta-analysis] PMID: 27978831
  22. Expression of IL-24 and IGFBP-3 significantly suppressed prostate cancer tumor growth in vivo. PMID: 26323436
  23. Blood IGFBP3 was lower in Black participants compared to Whites. PMID: 27455178
  24. The microRNA-125b level promotes invasive ability in p53-mutated cells via PI3K/AKT activation by targeting of insulin-like growth factor-binding protein-3. PMID: 28378642
  25. High expression of IGFBP3 is associated with metastasis in nasopharyngeal carcinoma. PMID: 27658775
  26. results indicated that miR-197 targeted IGFBP3 to induce the overgrowth and anti-apoptotic effects of Wilms tumor cells PMID: 27223680
  27. There is no interaction between IGFBP3 and MTA1 in ESCC, and they are not independent risk factors for esophageal squamous cell carcinoma prognosis. PMID: 27035126
  28. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma PMID: 26670461
  29. Study showed that IGFBP3 is dramatically induced in pancreatic tumors, and is abundantly produced in pancreatic cancer cells, causing muscle wasting through both impaired myogenesis via, at least, inhibition of IGF/PI3K/AKT signaling. PMID: 26975989
  30. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells via integrin beta1 signaling. PMID: 26540630
  31. endogenous IGFBP-3 is a p53 target that plays a role in breast cancer cell responsiveness to DNA damaging therapy PMID: 26378048
  32. Data indicate that IGF-binding protein 3 (IGFBP3) and F3 gene expression levels in formalin fixed paraffin embedded (FFPE) prostate cancer tissue would provide an improved survival prediction for prostate cancer patients. PMID: 26731648
  33. calcineurin in astrocytes was activated by Amyloid beta, leading to IGFBP-3 release. PMID: 26637371
  34. Circulating levels of IGF-1, IGFBP-3 and their molar ratio were not associated with the risk of occurrence of colorectal adenoma PMID: 26388613
  35. Independent of obesity, high insulin levels but reduced levels of IGFBP-3 were associated with increased lung cancer risk in current smokers. PMID: 27071409
  36. IGFBP-3 levels after ischemic stroke may independently predict functional outcome after one year. PMID: 26069074
  37. -202 A/C IGFBP3 polymorphisms did not show any consistent association with clinical and laboratory features of acromegalic patients even after treatment. PMID: 25552351
  38. polymorphism in IGFBP-3 rs2854744 A>C might be a potential predictor of esophageal squamous cell carcinoma risk and patient survival PMID: 26349977
  39. Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-beta. PMID: 26216267
  40. Authors demonstrate that IGFBP3 is a direct TAp73alpha (the p73 isoform that contains the trans-activation domain) target gene and activates the expression of IGFBP3 in actively proliferating cells. PMID: 26063735
  41. Methylation of IGFBP-3 in colorectal cancer was identified to be significantly associated with risk of recurrence. PMID: 25822686
  42. Data indicate that IGF binding protein-3 (IGFBP-3) reduced transcription of a variety of integrins, especially integrin beta4. PMID: 25945837
  43. Serum IGFBP3 was increased in hepatocellular carcinoma patients compared to patients with liver cirrhosis, but lower than in healthy controls. PMID: 26068014
  44. The current meta-analysis suggests that the IGFBP-3 C2133G polymorphism may confer susceptibility to colorectal cancer. [Meta-analysis] PMID: 25966104
  45. In women with normal somatotroph function, IGFBP3 levels do not change in the first trimester of pregnancy. PMID: 25179796
  46. Loss of IGFBP3 expression is associated with Colorectal Cancer. PMID: 25987030
  47. IGFBP-3 polymorphism is not a cause of delayed infancy-childhood transition in idiopathic short stature children. PMID: 25742716
  48. The functional IGFBP3 A-202C polymorphism may influence the susceptibility and progression of breast cancer in the Chinese population. PMID: 25960224
  49. Results suggest that immediately postexercise testosterone and IGFPB-3 responses are significantly increased after endurance training followed by strength training but not after strength training followed by endurance training. PMID: 25028991
  50. These findings indicate that IGFBP-3 enhances etoposide-induced cell growth inhibition by blocking the NF-kappaB signaling pathway in gastric cancer cells. PMID: 25662950
  51. Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis. PMID: 24928840
  52. IGFBP3 hypermethylation may serve as an independent prognostic and predictive biomarker in stage II and III CRC patients. PMID: 25127039
  53. IGFBP-3 thus has the ability to influence many cell functions through its interactions with intranuclear pathways, but the importance of these interactions in vivo. PMID: 26074086
  54. Early development of Beta-cell autoimmunity is linked to circulating IGFBP3 levels. PMID: 25947142
  55. Expression of IGFBP3 in several HCC cell lines was lower than in normal cell lines. Overexpression of IGFBP3 induced apoptosis and reduced colony formation. PMID: 25556430
  56. the interaction between IGFBP-3 and PPARgamma is important for the growth-inhibitory effect of PPARgamma ligands in human breast cancer cells PMID: 25449421
  57. The unmethylated IGFBP-3 promoter is associated with resistance to radiotherapy in patients with non-small cell lung cancer. PMID: 25482372
  58. Report association of IGFBP-3 gene polymorphism rs11977526 with longevity in Chinese nonagenarians/centenarians. PMID: 25553725
  59. IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression. PMID: 25081695
  60. IGFBP-3 inhibits TNF-alpha production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis in diabetic retinopathy. PMID: 25086184
  61. Here we review the literature on this paradoxical nature of IGFBP-3, its pro-apoptotic and growth-inhibitory actions versus its cytoprotective and growth-potentiating properties, and the implications of targeting IGFBP-3 for treatment of disease. [review] PMID: 24953254
  62. no significant association was found between IGF-1 and IGFBP-3 levels and disease activity, systemic inflammation, metabolic syndrome features, or adipokines. PMID: 25295265
  63. Data suggest development of islet autoimmunity and thus diabetes type 1 is subtly affected by early infant growth, however, IGFBP3 and IGF1/insulin-like growth factor I appear unlikely to be in causal pathway. PMID: 24785566
  64. Both serum IGF-1 and IGFBP-3 levels were significantly correlated with age, BMI, and serum c-peptide levels. serum IGFBP-3 levels showed significant correlation with HbA1c, total cholesterol, and LDL-cholesterol in the uncontrolled diabetic patients. PMID: 24825082
  65. Akt3 is a negative regulator of IGFBP-3 protein. PMID: 24942865
  66. IGFBP-3 -202A>C polymorphism might contribute to prostate cancer susceptibility, especially in Asian men and hospital-based studies [meta-analysis] PMID: 24457161
  67. The IGFBP3 polymorphism was associated with a higher baseline IGF1 in acromegaly. PMID: 25385818
  68. IGFBP-3 may not play an important role in resistance to EGFR-TKIs PMID: 24339922
  69. pioglitazone mediates regulation of IGFBP-3 via activation of PKA/DNA PK pathway in hyperglycemic retinal endothelial cells. PMID: 25525174
  70. Data suggest that combined inhibition of epidermal growth factor receptor and sphingosine kinase-1 has potential as an anticancer therapy in triple-negative breast cancer in which insulin-like growth factor-binding protein-3 expression is high. PMID: 24337110
  71. An association was found between -202 A/C polymorphism of IGFBP3 gene with VO2max in men. An association was found between -202 A/C polymorphism of IGFBP3 gene with VO2max in men. PMID: 24809065
  72. IGFBP-3 SNP rs2270628 may contribute to the risk of ESCC in the Chinese Han population. PMID: 24938707
  73. Data indicate insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a miR-21 target gene in glioblastoma and suggest that the oncogenic miRNA miR-21 down-regulates the expression of IGFBP3, which acts as a tumor suppressor in human glioblastoma. PMID: 25059666
  74. IGFBP-3 appears to exert a specific inhibitory effect on melanoma growth and dissemination PMID: 24905466
  75. Our results suggest that in conditions in which IGF-I levels are low, such as young age and in short small for gestational age children, IGFBP-3 proteolytic activity is increased to ensure IGF-I bioavailability. PMID: 24926947
  76. IGFBP-3 (rs3110697) was not associated with colorectal cancer risk in an Iranian cohort. PMID: 24175768
  77. IGFBP-3-202A/C gene polymorphism did not seem to be associated with any of the cancer sites in the various genetic models and ethnicities. (Meta-analysis) PMID: 24310658
  78. IGFBP-3 influences tumor cell proliferation, migration, and invasion and regulates STAT-1 expression in malignant glioma PMID: 24878287
  79. this meta-analysis demonstrates that there is no association of IGFBP-3 gene rs2854744 and rs2854746 polymorphisms with CRC risk. PMID: 24464126
  80. That IGFBP3 A-202C was a marginal risk factor of prostate cancer. PMID: 23464449
  81. HoxD10-targeted gene IGFBP3 has a role in suppressing gastric cancer cell invasion and favors the survival of gastric cancer patients. PMID: 24386080
  82. low blood IGFBP-3 is associated with atrial fibrillation in the elderly population and is an independent determinant of atrial fibrillation. PMID: 24368776
  83. High hepatic IGFBP-3 expression is associated with chronic hepatitis C. PMID: 23784592
  84. The IGF-I system is of significance in human Alzheimer disease. Serum but not CSF levels of IGFBP3 were higher in AD patients compared to controls. PMID: 23473966
  85. Data suggest that serum levels of free IGF1 (insulin-like growth factor-I) can be up-regulated by dietary factors (here, a 3-serving increase in milk consumption by postmenopausal women); total IGF1 and IGFBP3 levels in serum were unchanged. PMID: 24094144
  86. downregulation of IGFBP3 expression is associated with hepatocellular carcinoma. PMID: 23878061
  87. IGFBP-3 co-translocation to the nucleus of breast cancer cells and its formation of a complex with DNA-PKcs and EGFR in response to DNA damage shows its potential involvement in the regulation of DNA repair. PMID: 23178489
  88. Decreased IGFBP3 serum levels are associated with sepsis. PMID: 23611528
  89. These results suggest that NNK inhibits IGFBP-3 expression to abrogate anti-tumor actions of the IGFBP-3/IGFBP-3R system in smoking-induced lung cancer. PMID: 23498137
  90. IGFBP-3 and TNF-alpha levels were not associated with insulin sensitivity in women with polycystic ovary syndrome. PMID: 23864804
  91. Results suggested that interaction of SREBP-2 gene polymorphisms and the relationship between the polymorphisms and clinical phenotype of IGFBP-3 were closely related to increased ANFH risk in the Chinese population. PMID: 23158139
  92. Data indicate that IGFBP3 is abundantly secreted during prostatic stromal differentiation. PMID: 23720424
  93. Results show that IGFBP-3 stimulates autophagy and thereby promotes the survival of breast cancer cells exposed to conditions that represent the adverse microenvironments encountered by solid tumor cells in vivo. PMID: 22751133
  94. studies provide evidence that overexpression of IGFBP-3 suppresses osteoblastic differentiation regulated by VDR in the presence of 1,25-(OH)2D3 PMID: 23770368
  95. This is the first demonstration of the role of IGFBP-3 in inhibiting monocyte-endothelial cell adhesion. PMID: 23592916
  96. IGFBP3 A-202C and Gly32Ala polymorphisms are not associated with colorectal cancer susceptibility. PMID: 23527244
  97. The change of ADAM28 and IGFBP-3 gene expression is present in the normal tissue in overweight/obese patients with colorectal cancer only, and the observed variability of ADAM28 and IGFBP-3 expression may be an initial process of cancer proliferation PMID: 23527725
  98. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression might be used as an independent prognostic factor in the subgroup of OSCC. PMID: 22643116
  99. Results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. PMID: 22543588
  100. In patients with esophageal squamous cell carcinoma, reduced IGFBP-3 expression may be a risk factor for advanced clinicopathological classification and poor patient survival. PMID: 22167391

Show More

Hide All

Subcellular Location Secreted
Tissue Specificity Expressed by most tissues. Present in plasma.
Database Links

HGNC: 5472

OMIM: 146732

KEGG: hsa:3486

STRING: 9606.ENSP00000370473

UniGene: Hs.450230

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1